In addition, the results of the present study highlight for the first time the capability of nintedanib to significantly downregulate in vitro the activity of the profibrotic M2 macrophage phenotype obtained from SSc patients affected by ILD, by reducing gene expression and protein synthesis of cell markers (CD204, CD206 and CD163). The gene discussed is MSR1; the disease is systemic sclerosis.